ClinicalTrials.gg
Active, not recruitingNCT05575167EURODECUpdated Jul 22, 2026

Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)

An observational study in Osteoporosis, Postmenopausal, sponsored by 424 General Military Hospital. Active, not recruiting at 9 sites in 3 countries. Open to female participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by 424 General Military Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
122
Ages
50 Years to 85 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Osteoporosis, Postmenopausal with a site in Greece — 2 open to participants now, 3 under way, none of them phase 3. Osteoporosis, Postmenopausal · Greece.

Started
2023
with 1 other
Observational
7 of 14
2 open now
Registered
12th of 14
by date
Lead sponsor
4 of 14
424 General Military Hospital

Among the 14 studies in Osteoporosis, Postmenopausal with a site in Greece, this one is one of 2 that started in 2023, is one of 7 observational ones, and was the 12th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

2 of the 14 studies in Osteoporosis, Postmenopausal with a site in Greece are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →

Who these studies take

Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 50 Years to 85 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Osteoporosis, Postmenopausal with a site in Greece, or all of them as a file.
02

Study summary

A 24-month prospective, open-label, randomized, multicenter, multinational, non-inferiority pragmatic clinical trial evaluating zoledronate single or double infusion versus oral alendronate following denosumab

Read the detailed description

125 postmenopausal women treated with Dmab for 3 or more years who will reach osteopenia with denosumab will be randomized into three groups: i) zoledronate infusion (5mg) at 6 months after last Dmab dose (single Zol group) ii) zoledronate infusion (5mg) at 6 and 12 months after last Dmab dose (double Zol group) iii) alendronate 70mg orally weekly for 12 months (ALN group) All women will receive no further treatment during the 2nd year of the study.

Participating centers: ECTS affiliated bone centers

Endpoints: Primary: BMD changes at the lumbar spine at 12 months. Secondary: i) BMD changes at the lumbar spine at 24 months; ii) BMD changes at the non-dominant femoral neck and total hip at 12 and 24 months; iii) changes at levels of bone turnover markers throughout the study; iv) incident fractures: vertebral (clinical and morphometric identified on VFA scans) and non-vertebral; v) clinical parameters: height change, VAS for back pain, and use of analgesics

03

Conditions studied

  • Osteoporosis, Postmenopausal
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Postmenopausal women treated with denosumab

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women treated with denosumab for 3 or more years who will reach osteopenia

Exclusion criteria

Exclusion Criteria:

  • a bone disease other than osteoporosis
  • use of medications other than bisphosphonates or SERMS affecting bone metabolism during the last 12 months before entering the study
  • \<60 mL/min/1.73 m2
  • liver failure
  • any type of cancer
  • uncontrolled endocrine diseases
  • serum 25-hydroxy vitamin D (25-OHD) concentrations lower than 20 ng/mL (50 nmol/L)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
122 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • single Zol group

    postmenopausal women treated with denosumab for 3 or more years who will reach osteopenia with denosumab and will receive a single zoledronate infusion (5mg) at 6 months after the last denosumab dose

    Drug: Zoledronate or Alendronate

  • double Zol group

    postmenopausal women treated with denosumab for 3 or more years who will reach osteopenia with denosumab and will receive two zoledronate infusions (5mg) at 6 and 12 months after the last denosumab dose

    Drug: Zoledronate or Alendronate

  • ALN group

    postmenopausal women treated with denosumab for 3 or more years who will reach osteopenia with denosumab and will receive alendronate 70mg orally weekly for 12 months

    Drug: Zoledronate or Alendronate

Interventions

  • DrugZoledronate or Alendronate

    infusion (for zoledronate) or oral digestion (for alendronate)

    Also known as: Calcium and vitamin D supplementation

06

What researchers measure

Primary outcomes

  1. lumbar spine BMD

    BMD changes at the lumbar spine at 12 and 24 months

    Time frame: 24 months

Secondary outcomes

  1. femoral neck BMD

    BMD changes at the non-dominant femoral neck and total hip at 12 and 24 months

    Time frame: 24 months

  2. P1NP

    bone turnover (formation) marker

    Time frame: baseline, 3 months, 6 months, 12 months, 18 months, 24 months

  3. CTx

    bone turnover (resorption) marker

    Time frame: 24 months

  4. fracture

    incident fractures: vertebral (clinical and morphometric identified on VFA scans) and non-vertebral

    Time frame: 24 months

  5. height

    loss of height

    Time frame: 24 months

07

Study locations

9 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Jul 2027, 44 months after the start.

Of 23 observational studies under Osteoporosis, Postmenopausal, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 65. This study's planned 44 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2022
First posted
Oct 12, 2022
StartActual
Nov 28, 2023
Primary completionEst.
Jul 2027
CompletionEst.
Nov 2027
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05575167
Lead sponsor
424 General Military Hospital
Collaborators
Laikο General Hospital, Athens, 251 Hellenic Air Force & VA General Hospital, Campus Bio-Medico University
Responsible party
Athanasios D. Anastasilakis (Consultant of endocrinology; in charge of the Department of Metabolic Bone Diseases, 424 General Military Hospital) — Principal investigator
First posted
Oct 12, 2022
Start date
Nov 28, 2023
Primary completion
Jul 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Jul 22, 2026

Study contacts

Willem Lems, Prof
principal investigator · ECTS Clinical Action Group

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion